What is TARA's market cap?

$138.87M, based on the Nov 4 close of $2.35.

Does Protara Therapeutics pay a dividend?

No regular cash dividend has been paid in the last year.

How much of TARA is sold short?

6.1M shares, 11.5% of float, as of Oct 15, 2026.

What sector is TARA in?

Healthcare, in the Biotechnology industry.

NASDAQ · TARAHealthcareBiotechnology

Protara Therapeutics, Inc. Common Stock (TARA)

$2.35−2.49%

Close Nov 4, 2026 · split-adjusted

Nov 4, 2026$2.40▼ 53.13% in range

Nov 3, 2025Low $2.32 · High $7.56Nov 4, 2026

What changed · written from our data

As of Nov 4, 2026

Protara Therapeutics closed at $2.35 on Nov 4, down 2.49%, within 1.3% of its 52-week closing low. Volume of 352.5K shares was 0.35× its 20-day average (below normal).

Split-adjusted performance: -8.0% over one month, -58.5% over six months, -54.1% over one year.

Short interest was 6.1M shares at the Oct 15 settlement, up 5.2% from the prior report (11.5% of float, 4.3 days to cover).

Market cap$138.9M59.1M shares

Revenue · quarter$0.00—

Diluted EPS$-0.36—

P/E · TTM—

Net margin—

Dividend yieldNone

52-week range2.32 – 7.56−68.9% from high

Volume352.5K0.35× 20-day avg

Volatility · 60d48.4%Annualised

Short % of float11.5%4.3 days to cover

Net cash$142.5MCash $142.5M

Next earnings—Not scheduled

Split-adjusted performance

1W −5.6%1M −8.0%3M −42.7%6M −58.5%YTD −55.9%1Y −54.1%3Y +94.2%5Y −65.5%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum21

Revenue growth—

Net margin—

Value (low P/E)—

Size41

Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.

Short interest

Details →

Shares short6.1M+5.2% vs prior

Days to cover4.3Settled Oct 15

% of float11.5%

Short vol. 10d27.2%of daily volume

Closest peers by size in Biotechnology

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
TARAProtara Therapeutics	$2.35	−2.49%	−58.5%	—	—	—	$138.9M
CMPXCompass Therapeutics	$0.7627	+1.29%	−59.2%	—	—	—	$137.4M	Compare
CHRSCoherus Oncology	$0.8502	+5.54%	−51.4%	+39.5%	−144.2%	—	$131.4M	Compare
HUMAHumacyte	$0.4500	+2.16%	−54.2%	+34.9%	−9064.5%	—	$125.0M	Compare
STROSutro Biopharma	$9.94	+4.52%	−73.6%	−84.6%	−391.6%	—	$164.8M	Compare
AVXLAnavex Life Sciences	$1.26	+5.00%	−62.3%	—	—	—	$116.8M	Compare
ARMPArmata Pharmaceuticals	$3.14	+1.62%	−65.3%	+15.7%	2953.8%	—	$116.8M	Compare
ENGNenGene Therapeutics	$1.72	+6.17%	−80.6%	—	—	—	$115.3M	Compare
VYGRVoyager Therapeutics	$1.87	+2.19%	−55.2%	−39.1%	−773.2%	—	$115.2M	Compare

News about Protara Therapeutics

All news →

Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBCGlobeNewswire Inc. · May 15, 2026▲ Positive Protara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business UpdateGlobeNewswire Inc. · Mar 10, 2026▲ Positive

Quick answers

What does Protara Therapeutics do?: Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.
What is TARA's market cap?: $138.87M, based on the Nov 4 close of $2.35.
Does Protara Therapeutics pay a dividend?: No regular cash dividend has been paid in the last year.
How much of TARA is sold short?: 6.1M shares, 11.5% of float, as of Oct 15, 2026.
What sector is TARA in?: Healthcare, in the Biotechnology industry.

About Protara Therapeutics

Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.

HQ: New York, NY51 employeesListed Jan 10, 2020protaratx.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology